Scinai Immunotherapeutics Ltd ADR SCNI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCNI is a good fit for your portfolio.
News
-
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
-
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
-
Scinai leadership to attend BIO-Europe Spring 2024
-
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
-
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.48–0.48
- 52-Week Range
- $0.43–2.27
- Bid/Ask
- $0.44 / $0.48
- Market Cap
- $2.07 Mil
- Volume/Avg
- 669 / 26,862
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.biondvax.com
Valuation
|
Metric
|
SCNI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SCNI
Financial Strength
|
Metric
|
SCNI
|
|---|---|
Quick Ratio | 4.28 |
Current Ratio | 4.36 |
Interest Coverage | — |
Quick Ratio
SCNI
Profitability
|
Metric
|
SCNI
|
|---|---|
Return on Assets (Normalized) | −37.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −52.86% |
Return on Assets
SCNI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mvwyvmjxh | Xrbl | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dcjsdmkrx | Cwszxzy | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fmwlksrb | Vddnct | $103.3 Bil | |
MRNA
| Moderna Inc | Nxpfjlfvx | Jrhpx | $48.1 Bil | |
ARGX
| argenx SE ADR | Ynjvpgyvz | Chxjw | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Wpbfjgv | Xhvvc | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzxldscq | Fhqpcmg | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Djbvgsc | Mhbzv | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Knpwgcdmfg | Tqbbdp | $12.7 Bil | |
INCY
| Incyte Corp | Dvllzys | Gpcfnh | $11.9 Bil |